NCT06485713

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib Versus Trifluridine/Tipiracil and Fufuquitinib for Third-line Treatment of Unresectable Metastatic Colorectal Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: First Affiliated Hospital of Wenzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.

Conditions

• Metastatic Colorectal Cancer
• Drug Therapy

Interventions

Type	Name	Description
DRUG	trifluridine/tipiracil combined with fufuquitinib	trifluridine/tipiracil combined with fufuquitinib
DRUG	fufuquitinib	fufuquitinib
DRUG	Trifluridine/tipiracil	Trifluridine/tipiracil

Timeline

• Start date: 2024-03-01
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2024-07-03
• Last updated: 2024-07-03

Locations

1 site across 1 country: China